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ABSTRACT 
 
Type I interferon (IFN) gene therapy modulates the immune 
response leading to inflammatory heart disease following 
cytomegalovirus (CMV) infection in a murine model of post-
viral myocarditis. Efficacy of different immunisation protocols 
for the IFN constructs was influenced by the dose of DNA, 
subtype choice, combination use, pre-medication, and timing 
of DNA administration. Optimal efficacy was found with 
bupivacaine treatment prior to DNA inoculation of 200µg IFN 
DNA 14 days prior to virus challenge. Maximal antiviral and 
antimyocarditic effects were achieved with this vaccination 
schedule. Furthermore, inoculation of synergistic IFN subtypes 
demonstrated enhanced efficacy when delivered either alone or 
with CMV gB DNA vaccination in the CMV model. Thus 
naked DNA delivery of IFN provides an avenue of 
immunotherapy for regulating herpesvirus-induced diseases. 
 
INTRODUCTION 
 
Cytomegalovirus (CMV) is a herpesvirus that causes latent and 
persistent infection. This virus may induce inflammation of the 
heart known as myocarditis, which may lead to dilated 
cardiomyopathy, arrhythmias and sudden death. Currently, 
there is no effective safe vaccine for CMV, as the vaccines 
studied so far, only provide partial protective immunity upon 
challenge with infectious virus. Vaccines for viral infections 
and diseases have encompassed live attenuated viruses, subunit 
virions, recombinant viral proteins/peptides and recently viral 
DNA constructs. Interest in cytokines has increased with the 
aim of seeking improvement of the efficacy of such viral DNA 
vaccines. Nonetheless, optimization of DNA delivery is an 
important aspect of vaccine development. Specifically in the 
case of DNA vaccines, factors including DNA dosage, choice 
of cytokine genes, pre-medication, and timing of DNA 
administration can influence the immune response following 
intramuscular (i.m.) vaccination. 
 
Many studies of murine models have found that effective DNA 
vaccination occurs in a dose-dependent manner, generally with 
a dose range of 25-200µg plasmid DNA (1-4). Previously, we 
have found in vivo expression of interferon alpha (IFNA) genes 
following i.m. inoculation of 200µg naked DNA to be effective 
against murine cytomegalovirus (MCMV) infection. This 
approach also allows us to examine the superiority of 
individual and combinational usage of different IFN subtypes 
within the multigene family (5-9). Other groups using type I 
IFN-expressing plasmids have reported effective inoculation 
with 100µg i.m. (10) or 100µg/eye (11) in cancer and herpes 
simplex virus (HSV) infection, respectively. In addition, 
investigators have found a dose-response effect of pCMV-
IFNα1 plasmid on HSV-1 replication in the range of 25-
100µg/eye (11).  
 
The choice of cytokines is very important in providing 
protective immunity via immunotherapy. Since type I IFNs 
belong to a multigene family, we examined the effect of seven 
individual IFN subtypes (IFNA1, A2, A4, A5, A6, A9 and B), 
administered by DNA inoculation, on systemic MCMV 
infection and myocarditis (8). We found that IFNA6 treatment Bartlett et al.   44 
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reduced MCMV replication whilst IFNA5 and A2 treatment 
enhanced virus replication. Moreover, IFNA6, A9, and B 
treatment inhibited acute myocarditis whilst IFNA6 was able to 
also reduce chronic cardiac inflammation. In addition, viral 
DNA vaccines encoding the CMV glycoprotein B (gB) are 
currently being investigated and require improved efficacy. We 
have previously studied the efficacy of the gB DNA vaccine 
with the application of type I IFNs, IFNA6, IFNA9 and IFNB 
(9). CMV-induced myocarditis was preferentially reduced with 
either IFNA9 or IFNB but not with IFNA6, coimmunisation. 
However, IFNA6, IFNA9 and IFNB markedly reduced chronic 
myocarditis in CMV gB-vaccinated mice. 
 
Pre-medication with bupivacaine prior to DNA inoculation is 
also a factor in the optimization of the DNA inoculation 
protocol. Bupivacaine is an anaesthetic which destroys 
myofibres, induces myogenesis and is reported to enhance 
protein expression following DNA inoculation since 
regenerating muscle is thought to encourage DNA uptake (12). 
Reports of the effect of bupivacaine pre-medication on 
transgene expression demonstrate conflicting evidence with 
some reports suggesting no effect and some observing up to 
40-fold increase in gene expression (6, 12).  
 
Previous reports have demonstrated that the timing of DNA 
inoculation contributes to therapeutic outcome. In particular, 
timing of DNA inoculation can influence the type of Th cell 
response induced. This was first demonstrated with plasmid 
encoded GM-CSF (pGM-CSF) co-administered with DNA 
encoding the envelope protein of HIV. Inoculation of pGM-
CSF 3 days prior to DNA vaccination induced a predominantly 
Th2-type immune response, simultaneous administration with 
antigen induced both a Th1 and Th2 type response and 
inoculation 3 days after DNA vaccination stimulated a 
predominantly Th1 response (13). A similar effect has since 
been observed with plasmid administered IL-12 in models of 
HIV and Leishmania vaccination (1, 2). Similarly, previous 
studies in our laboratory have demonstrated variability in the 
immunomodulatory efficacy of type I IFN subtype transgenes, 
which is dependent on the timing of DNA inoculation in 
relation to MCMV challenge (5). 
 
In this study, we determined the optimal inoculation schedule 
for type I IFN subtype DNA constructs in the MCMV model of 
infection and disease. We found that DNA dosage, bupivacaine 
pre-medication, and timing of DNA inoculation (5), were 
contributing factors in the therapeutic efficacy of IFN DNA 
therapy in regulating herpesvirus infection and disease 
sequelae. Furthermore, we examined the synergistic effects of 
gB, IFNA6 and IFNB compared to that of the gB DNA vaccine 
alone. We found that the combined gB/IFNA6/IFNB DNA 
vaccine was superior to the gB  DNA vaccine in providing 
protection from MCMV infection. Further applications of the 
synergistic properties provided by type I IFNs may be used in 
conjunction with other viral DNA vaccines for improved 
vaccine efficacy.  
 
MATERIALS AND METHODS 
 
Mice 
 
Specific pathogen-free inbred male BALB/c mice of 4 weeks 
of age were supplied by the Animal Resources Centre 
(Murdoch, Western Australia).  
 
Virus 
 
The K181 strain of MCMV was prepared as a salivary gland 
homogenate by passage through 3-week-old female BALB/c 
mice and stored under liquid nitrogen. MCMV titres in target 
organs were quantitated by plaque assay using mouse M2-
10B4 stromal cells. Virus titres are expressed as mean pfu/g 
tissue ± SEM (5 mice per group). The limit of detection was 
100 pfu/g for liver and spleen and 6400 pfu/g for salivary 
gland tissue. 
 
Expression plasmid DNA constructs 
 
IFN subtype genes and the full-length gB MCMV gene were 
cloned into the mammalian expression vector, pkCMVint 
(VICAL, San Diego, CA) as previously described (8, 9). 
Large-scale plasmid preparations were obtained from terrific 
broth cultures of transformed E.coli (DH-5α) using standard 
DNA extraction procedures with LiCl precipitation. DNA 
integrity was checked by agarose gel electrophoresis and 
concentrations determined by spectrophotometric analysis. 
 
DNA immunisation and virus challenge protocol 
in vivo 
 
To induce muscle regeneration, mice were injected bilaterally 
with 20µL 0.5% bupivacaine 5 days prior to inoculation of 
DNA constructs (either 50, 100, 200 or 400µg/mouse as 
indicated). DNA was diluted in a 50µL volume of pyrogen-free 
saline and injected bilaterally in tibialis anterior (TA) muscles. 
Mice were either treated with the Blank expression vector or 
vectors expressing IFN subtypes (IFNA6, A9 and B) or the gB 
transgene alone or in combination. At 14 days post DNA-
treatment, mice were inoculated with 100µL of 1x10
4 pfu 
MCMV, diluted in pyrogen-free saline, by the intraperitoneal 
(i.p.) route (5 mice/group). At days 3, 7, 10 and 56 post-
infection (p.i.), tissues were collected. Deviations from this 
standard protocol are stated in the results and figure legends. 
 
Myocarditis analysis 
 
Hearts from infected mice were removed at day 7 and 56 p.i., 
transected along the midline and fixed overnight in Bouin’s 
fluid, transferred to 70% ethanol and then processed into 
paraffin blocks. Sections were stained with haematoxylin and 
eosin (H&E) and evaluated for evidence of cellular 
inflammation and necrosis as previously described (8). Two 
heart sections were scored for each animal. Myocarditis was Bartlett et al.   45 
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evaluated histologically as the mean number of inflammatory 
foci per heart section ± SEM (5 mice/group). 
 
Statistical analysis 
 
Levels of significance (p<0.05) were determined by the 
unpaired student t-test assuming unequal variance between the 
means. 
 
RESULTS AND DISCUSSION 
 
Results 
 
Importance of IFN dose for efficacy of DNA delivery 
in vivo  
 
Previously, we have demonstrated efficacy using 200µg IFN 
transgenes inoculated i.m. Here, we evaluated IFN transgene 
inoculation using lower doses of DNA for therapeutic efficacy 
in reducing virus titres and cardiac inflammatory foci. Mice 
were treated with either 50µg or 100µg Blank, IFNA6 or IFNB 
DNA and challenged with a sublethal dose of MCMV (1x10
4 
pfu i.p.). The effect of low doses of IFNA6 and IFNB on early 
MCMV replication and acute-phase myocarditis was evaluated 
in comparison to the Blank vector. Acute-phase viral titres 
were determined by plaque assay of spleen and liver 
homogenates at day 3 p.i. and salivary gland homogenates at 
day 7 p.i. and acute phase myocarditis was evaluated at day 7 
p.i. 
 
The antiviral efficacy previously demonstrated by these IFN 
subtypes at 200µg per mouse (8) was suppressed at these lower 
doses. More specifically, IFNA6 and IFNB DNA had no 
significant effect on viral titres in any tissue examined (Fig. 
1A, B and C). IFNA6 at 50µg reduced liver titres by only 1.6-
fold and at 100µg marginally reduced both spleen (2.0-fold) 
and liver (1.3-fold) titres compared to Blank-vector treated 
mice. Whereas, treatment with IFNA6 at 200µg was most 
effective with significant reductions of 5.7- and 19-fold of 
virus titres in the spleen and liver, respectively. However, 
treatment with IFNB at either 50µg, 100µg or 200µg did not 
affect virus titres in any tissue tested. Administration of 200µg 
of either IFNA6 or IFNB has been previously associated with 
suppression of acute stage myocarditis with 4.7- and 2.4-fold 
reduction, repectively compared to Blank vector-treated mice 
(8). Here, we show that myocarditis was also significantly 
reduced with inoculation of 50µg/mouse of either IFNA6 (4.3-
fold) or IFNB (1.7-fold) DNA in comparison to Blank vector-
treated mice. However, treatment with 100µg  IFN was not 
effective with only a 1.4-fold reduction in comparison to 
control groups (Fig. 1D). Similar to our previous findings, viral 
titre was not an indicator of disease. In brief, reducing the dose 
of  IFN DNA to 50µg/mouse or 100µg/mouse reduced the 
antiviral and antimyocarditic efficacy of IFNA6 and IFNB that 
we have previously observed with the higher dose of 
200µg/mouse in the treatment of MCMV infection and 
myocarditis. 
 
 
 
 
 
Fig. 1: The effect of DNA dosage in IFN  transgene treatment of MCMV 
infection and myocarditis. Bupivacaine-treated BALB/c mice were inoculated 
with doses of either 50µg or 100µg of Blank, IFNA6 or IFNB DNA at 14 days 
prior to viral challenge with 1x10
4  pfu of MCMV i.p. Viral titres were 
determined by plaque assay in (A) spleen and (B) liver at day 3 p.i. and (C) 
salivary glands at day 7 p.i. Results are expressed as mean pfu/g ± SEM (n=5). 
(D) Myocarditis was evaluated at day 7 p.i. and is expressed as the number of 
foci per heart section ± SEM (n=5). *, Statistical significance (p≤0.05) 
compared with Blank treatment groups. 
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Assessment of DNA dose in co-administration of 
synergistic IFN subtypes 
 
The effect of combining two type I IFN subtypes was 
examined for determination of their possible synergistic 
efficacy in abrogating MCMV replication and disease. 
Previously we found synergistic properties of effective type I 
IFN subtypes when administered in combination (5). 
Combinations of Blank, IFNA6, IFNA9 and IFNB DNA were 
examined for their antiviral and antimyocarditic efficacy. In 
separate studies, BALB/c mice were inoculated i.m. with 
200µg of each DNA construct (total 400µg DNA/mouse) or 
with 100µg of each DNA construct (total 200µg DNA/mouse) 
14 days prior to challenge with 1x10
4 pfu MCMV by the i.p. 
route. Efficacious IFN inoculation was demonstrated only at 
the lower dose of 200µg total DNA, as previously described 
(5), while the dosage of 400µg total DNA suppressed the 
efficacy associated with individual administration of these IFN 
subtypes.  
 
In terms of antiviral efficacy, the 400µg IFNA6/Blank 
combination was not as effective as 200µg IFNA6 alone. In 
target tissues, IFNA6/Blank treatment showed no significant 
change with only a 1.8-fold maximum reduction in virus titres 
(Fig, 2A, B, C) compared to IFNA6 alone treatment, resulting 
in 5.7-, 19- and 1.5-fold reductions in virus titres in the spleen, 
liver and salivary glands, respectively. The IFNA9 and IFNB 
treatments had no significant effects on viral titres with the 
exception of IFNB/Blank treatment at 400µg which 
significantly increased liver titres by 2.2-fold at day 3 p.i. (Fig. 
2B) as opposed to no significant change with 200µg IFNB 
alone at this timepoint. Overall, the 400µg combination of 
IFN/Blank did not demonstrate the level of antiviral protection 
observed with 200µg individual and combination IFN 
treatment, as previously described (5, 8). 
 
In addition, we have previously described the synergistic 
properties of effective IFNs (IFNA6, A9 and B) in combination 
to a total of 200µg DNA. Here, we also demonstrate that doses 
of 400µg DNA in combination is inferior for antiviral and 
antimyocarditic efficacy. Specifically, in the spleen, 200µg 
IFNA6/A9 reduced virus titres 3.0-fold and IFNA6/B reduced 
virus titres 50-fold while 400µg of each of these IFN 
combination reduced virus titres by only 1.6-fold and 1.3-fold, 
respectively. Similarly, in the liver, 200µg IFNA6/B reduced 
virus titres 3.2-fold and IFNA9/B reduced virus titres 2.7-fold 
while 400µg of these DNA vaccines marginally enhanced virus 
titres by 1.8-fold and 1.5-fold, respectively. IFN combinations 
had no detectable antiviral effects in the salivary glands. 
 
 
 
 
 
Fig. 2: Co-treatment with 400µg  IFN subtype DNA does not affect acute-
phase MCMV infection or myocarditis. Bupivacaine treated BALB/c mice 
were inoculated with Blank vector or combinations of IFNA6/Blank, 
IFNA9/Blank, IFNB/Blank, IFNA6/A9, IFNA6/B, and  IFNA9/B DNA at a 
dosage of 200µg per transgene to a total of 400µg DNA, bilaterally via the TA 
muscle. At 14 days post-inoculation, mice were challenged with 1x10
4 pfu 
MCMV i.p. Viral titres were determined in (A) spleen and (B) liver at day 3 
p.i. and (C) salivary glands at day 7 p.i. and are expressed as pfu/g tissue ± 
SEM (n=5). (D) Myocarditis was evaluated at day 7 p.i. and is expressed as the 
number of foci per heart section ± SEM (n=5). *, Statistical significance 
(p≤0.05) compared with Blank treatment groups. Bl. denotes Blank expression 
vector. 
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IFN treatment at 400µg DNA/mouse had no effect on acute 
phase MCMV-induced myocarditis with the exception of the 
IFNA9/B treatment combination, which reduced disease 
severity by 2.5-fold (Fig. 2D). However, this compared to a 
reduction in disease of 5.3-fold following administration of 
200µg  IFNA9/B and therefore is suboptimal. Notably, no 
significant reduction in acute myocarditis was observed with 
either  IFNA6/Blank (1.2-fold), IFNA9/Blank (1.3-fold) or 
IFNB/Blank (1.3-fold, Fig. 2D) despite the protective effect 
previously observed following DNA treatment with these 
subtypes at doses of 200µg/mouse with reductions of 4.7-, 2.0- 
and 2.4-fold, respectively (8). Thus co-inoculation of effective 
type I IFNs with Blank vector at a total of 400µg/mouse 
resulted in abrogation of efficacy previously observed in this 
animal model. 
 
Pre-medication with bupivacaine is critical for 
IFNA6 immunotherapy  
 
We have previously demonstrated the superior efficacy of 
IFNA6 inoculation, which has potent antiviral effects and 
reduces disease pathogenesis in the MCMV model (8). Our 
standard inoculation protocol includes the treatment of mice 5 
days prior to DNA inoculation with 20µL 0.5% bupivacaine 
given bilaterally to the TA muscles. Here, we investigated the 
necessity of bupivacaine treatment prior to IFNA6 
administration. Mice were either treated or not treated with 
bupivacaine 5 days prior to IFNA6  DNA inoculation and 
subsequently challenged with 1x10
4 pfu MCMV. The effect of 
bupivacaine treatment on the antiviral response and 
myocarditis was evaluated.  
 
Treatment with the IFNA6 transgene with bupivacaine 
demonstrated reduced MCMV titres in the spleen and liver at 
day 3 p.i. (Fig. 3A and B) and the salivary gland at day 7 p.i. 
(Fig. 3C). However, without the administration of bupivacaine, 
a significant reduction in MCMV was observed only in the 
liver at day 3 p.i. (Fig. 3B) with no effect observed in other 
tissues. Similarly, IFNA6 inoculation significantly reduced 
acute-phase myocarditis whilst IFNA6 administration without 
bupivacaine had no effect on disease severity in the 
myocardium (Fig. 3D). Therefore, maximal efficacy for 
MCMV infection was achieved with bupivacaine pre-
medication i.m. 
 
 
 
 
 
Fig. 3: IFN  DNA inoculation without bupivacaine treatment is ineffective 
against MCMV infection and myocarditis. BALB/c mice were either not 
treated (No Bp) or treated (Bp) with bupivacaine 5 days prior to DNA 
inoculation with 200µg of either Blank or IFNA6 vector DNA and 
subsequently challenged with 1x10
4  pfu of MCMV i.p 14 days later. Viral 
titres were determined by plaque assay in (A) spleen and (B) liver at day 3 p.i., 
and (C) salivary glands at day 7 p.i. Results expressed as % Blank treatment 
group ± SEM (n=5). (D) Myocarditis was evaluated at day 7 p.i. and is 
expressed as the number of foci per heart section ± SEM (n=5). *, Statistical 
significance (p≤0.05) compared with Blank treatment groups. 
 
Combinational IFN immunotherapy for CMV gB 
DNA vaccination 
 
Previous studies have revealed the capacity of specific type I 
IFN DNAs, when co-immunised with gB DNA, to enhance the 
protection afforded by the gB DNA vaccine against MCMV 
replication (9). Here we examine the capacity of 
gB/IFNA6/IFNB to enhance the protection previously observed 
against MCMV infection afforded by gB DNA vaccines (9), 
DNA encoding specific IFN subtypes (8), and combinations of 
IFN subtypes (5). Each mouse was infected with 1x10
4 PFU of 
MCMV 14 days post-vaccination with either Blank (200µg), Bartlett et al.   48 
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gB (200µg) or combination gB/IFNA6/IFNB (50µg, 50µg, 
100µg respectively) DNA constructs. The addition of the IFN 
combination as adjuvant to the gB vaccine did not alter the 
vaccines antiviral efficacy in the spleen (Fig. 4A). However, 
inoculation of IFNA6/IFNB DNA with gB led to a significant 
reduction in MCMV replication in the liver at day 7 p.i. (Fig. 
4B). In addition, the combined gB/IFNA6/IFNB DNA vaccine 
significantly decreased both acute (Fig. 4C) and chronic (Fig. 
4D) myocarditis in comparison to the Blank and gB  DNA 
vaccinated groups.  
 
Discussion 
 
Here we describe a detailed study focusing on optimization of 
the inoculation protocol for type I IFN subtype DNA 
constructs in the MCMV model. Delivery of either individual 
or combination IFN subtypes allows for investigation of the 
biological function and synergy of IFN in vivo. In addition, the 
delivery of IFN DNA subtypes can be examined for 
enhancement of protective immunity afforded by viral 
vaccination of mice. 
 
Contributing factors for effective DNA treatment examined in 
this study included optimal dose determination for IFN DNA 
inoculation. Previous studies in our laboratory using 
mammalian expression plasmid administered IFNα have 
effectively used inoculations of 200µg DNA (5-8). Data 
presented in this study demonstrates that lower doses of 50µg 
and 100µg type I IFN DNA, inoculated 14 days prior to virus, 
were ineffective in reducing viral replication. Interestingly, 
50µg DNA effectively reduced acute myocarditis while 100µg 
IFN  had no effect. Co-inoculation of effective type I IFNs 
(total 400µg/ mouse) resulted in abrogation of the antiviral 
efficacy and suppression of disease previously observed in this 
model (5, 8). It may be that excess doses of IFN DNA (400µg) 
render the IFN DNA treatment ineffective at reducing antiviral 
titres and myocarditis and altering cytokine profiles. The 
exception to this was treatment with IFNA9/B, which reduced 
disease (2.5-fold) and circulating IFNγ titres (data not shown), 
however, this was not as effective as the 200µg combination 
IFNA9/B  which reduced myocarditis by 5.3-fold (5). 
Therefore, dosage of DNA was found to be crucial for 
therapeutic outcome. In this study, we have demonstrated that 
both insufficient and excess DNA suppressed the efficacy of 
type I IFN DNA treatment. Dose-response curves from 
previous studies demonstrate optimal DNA doses at 100-200µg 
with decline in efficacy at higher concentrations (14). Effective 
gene immunotherapy has previously been demonstrated with 
doses of 200µg/mouse for IFNγR-Fc (15) and IL-4/IgG1 (16) 
and type I IFNs (7). Similarly, we have shown that type I IFN 
DNA inoculation is most effective at 200µg/mouse, 
administered both as individual subtypes and as combination 
treatments. This indicates that effective type I IFN DNA 
inoculation is dose-dependent which is consistent with findings 
in other models of DNA vaccination (1, 13). 
 
 
 
 
 
Fig. 4: Combinational IFN DNA co-administration with gB improves vaccine 
efficacy  in vivo. BALB/c mice were vaccinated with either Blank,  gB, or 
gB/IFNA6/IFNB DNA (200µg/mouse) 14 days prior to i.p. inoculation with 
1x10
4  pfu of MCMV. Viral titres were determined by plaque assay in (A) 
spleen at day 3 p.i. and (B) liver at day 7 p.i. Myocarditis was evaluated at (C) 
day 10 p.i. and (D) day 56 p.i. Myocarditis is expressed as the number of foci 
per heart section ± SEM (n=5). *, Statistical significance (p≤0.05) compared 
with gB DNA vaccinated group. 
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It is widely believed that inoculation of DNA constructs into 
regenerating muscle contributes to enhanced uptake and 
expression of transgenes (12, 17). Bupivacaine treatment is an 
efficient inducer of myogenesis prior to plasmid inoculation 
(12), however, evidence for and against this treatment is 
conflicting. In this study, plasmid administration without 
bupivacaine treatment was generally ineffective for all aspects 
evaluated with the exception that IFNA6 reduced viral titres in 
the liver. Despite this, viral titres in the liver were 9.4-fold 
greater in the group not treated with bupivacaine compared to 
the bupivacaine treated group. Similarly, viral titres following 
IFNA6 inoculation without bupivacaine treatment increased 
7.8-fold and 2.8-fold in the spleen and salivary gland 
respectively compared to the bupivacaine treated group. 
Furthermore, myocarditis increased 3.5-fold without 
bupivacaine treatment compared with bupivacaine treatment 
following IFNA6 treatment. Therefore, we demonstrated that 
bupivacaine treatment is a necessary component of the optimal 
inoculation program in DNA inoculation in the MCMV model. 
 
We previously investigated the timing of DNA administration 
and demonstrated that optimal efficacy was achieved when 
mice were treated with IFN  DNA 14 days prior to viral 
challenge (5). Treatment with IFNA6 and IFNB 2 days before 
and 2 days after viral infection proved ineffective during the 
acute phase of viral infection and disease. Interestingly, IFN 
DNA treatment 2 days prior to viral infection reduced the 
chronic phase of myocarditis. The limited efficacy of IFN 
treatment at these time-points, however, is largely expected 
given that systemic IFN expression peaks at day 28 following 
IFN treatment and is not significantly increased in comparison 
to Blank groups until day 14 (5). In addition, endogenous IFN, 
produced as part of the immune response to viral invasion, 
peaks 2 days following LCMV infection and may therefore 
mask IFN transgene expression at this time (18). We postulate 
that type I IFN administrated at later time-points is 
insufficiently expressed prior to endogenous cytokine 
production in response to virus. Surprisingly, IFNB treatment 2 
days prior to virus contributed to a pathogenic immune 
response.  Indeed, another study has demonstrated a distinct 
role for IFNβ as an “immediate-early response gene” following 
viral infection. This group suggests that IFNβ must be 
synthesized for induction of a delayed IFN gene set (including 
α2, α5, α6 and α8) (19). Potentiation of IFNα cytokines by 
IFNβ may exacerbate the immune response and lead to 
detrimental responses in this model. 
 
Finally, the optimization of the IFN DNA inoculation protocol 
was trialed as adjuvant immunotherapy for a CMV-specific 
DNA vaccine. Clearly, this study confirms the superiority of 
the combined viral gB/IFNA6/IFNB DNA vaccine to that of the 
viral gB DNA vaccine in providing protection from MCMV 
infection and myocarditis. Strikingly, the synergistic effects of 
the gB/IFNA6/IFNB DNA vaccine were found to significantly 
decrease inflammation within the myocardium during both the 
acute and chronic phases to levels previously seen in MCMV-
infected C57BL/6 mice which are resistant to the development 
of post-viral myocarditis (20). This research into the 
synergistic effects of the gB/IFNA6/IFNB DNA vaccine has 
revealed the potential of specific IFNs and immunogenic 
proteins to act as an enhanced immunotherapy when combined 
and administered as a single DNA vaccine.  
 
Our observations using 200µg DNA/mouse show that 
treatment with gB/IFNA6/IFNB DNA was ineffectual in 
comparison to IFNA6/IFNB (5) and gB/IFNB (9), at decreasing 
MCMV replication in target organs. However, results from 
these previous studies revealed no correlation between virus 
load and subsequent development of acute myocarditis. Co-
immunisation of IFNA6/IFNB reduced viral titres in both 
spleen and liver, with no improvement in acute phase 
myocarditis, but reduced myocarditis in the chronic phase (5). 
Whereas, co-immunisation with gB/IFNB caused significantly 
reduced MCMV titres in target organs as well as reduced acute 
and chronic phase myocarditis (9). Therefore results from this 
study and previous experiments follow the speculation of viral 
load in target organs not affecting acute phase myocarditis, but 
possibly being a factor in the latter stage development of 
autoimmune myocarditis. Furthermore, the gB/IFNA6/IFNB 
vaccine was found to be of similar efficacy to the gB/IFNB 
vaccine in the general suppression of MCMV-induced 
myocarditis. Thus viral gB/IFNB vaccination using our 
optimised delivery of DNA constructs would be the preferred 
treatment of choice. 
 
Therapeutic application of combined IFN subtypes to DNA 
vaccines may provide an extensive array of new possibilities 
for future research into protection from diseases that were 
otherwise thought incurable or exhaustive of any further 
applications. Clinical trials into DNA viral vaccines for HIV 
and influenza virus have arisen due to the urgent need for a 
protective vaccine for these infectious diseases. Trials have 
used DNA vaccines encoding viral proteins such as influenza-
specific hemagglutinin (21), and HIV-specific gp120 and 
gp160 (22), shown only to provide partial protection. However, 
with the knowledge gained on type I IFNs and their synergistic 
properties from our studies, the application of combined IFNs 
could possibly be used in improving the efficacy of these DNA 
vaccines. 
 
In summary, we describe in this study the optimization of 
intramuscular expression of DNA transgenes encoding IFNα/β 
subtypes for improved protection of mice from MCMV-
induced myocarditis. We have successfully utilised the DNA 
delivery method to examine the therapeutic antiviral and 
antimyocarditic effects of both individual and combinational 
IFN subtypes in vivo. This experimental system can also be 
applied in DNA vaccine trials to study the therapeutic efficacy 
of type I IFN subtypes in host protection from other virus 
infections. 
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PROTOCOLS 
 
Protocol 1: Large-scale preparation of plasmid DNA 
 
Reagents: 
 
Terrific broth (Solution A: 1.3% Tryptone Peptone (w/v) [Difco #211705]; 2.67% Yeast extract [Becton Dickinson #211929]; 
0.44% Glycerol (v/v) [Univar #242-500ML]; Solution B: 719mM K2HPO4[BDH AnalaR #104363A]; 169mM KH2PO4[Univar 
#391-500G]). Autoclave solution A and B separately. Combine the two solutions at a ratio of 9:1 respectively. 
TEG swelling buffer (25mM Tris [Invitrogen #15504-020], pH8.0; 10mM EDTA [BDH AnalaR 10093.5V]; 0.9% Glucose (w/v) 
[Univar #783-500G]). Store at 4
oC. 
Lysis Buffer (0.2M NaOH [Univar #482-500G]; 1% SDS [BDH GPR #301754L]). Prepare just prior to use. 
High Salt Neutralisation buffer (2.5M Potassium acetate [BDH #295814P]; 5% Formic acid (v/v) [Univar #2471-500]). 
LiCl solution (5M LiCl [BDH GPR #290674B]; 1% MOPS (w/v) [Sigma #M-9024], pH to 8.0). Autoclave and store at 4
oC. 
Tris-buffered phenol. Melt phenol [Sigma # P-1037] at 65
oC and extract with 1M Tris, pH 8.0 by stirring O/N. Change buffer 3 
times over a 24h period or until pH of the aqueous phase is >7.6. Extract once more with 0.1M Tris, pH 8.0 and store under 
equilibrium buffer @ 4
oC in the dark. 
Phenol/ chloroform/isoamyl alcohol (25:24:1). Add an equal volume of chloroform [Sigma #C-2432]/isoamyl alcohol [Sigma #1-
3643] (24:1 v/v) to Tris-buffered phenol and store under 0.1M Tris, pH8.0 at 4
oC in the dark. 
Isopropanol [Univar #425-2.5] 
Ethanol [Sigma #E-7023] 
RNase, DNase-free [Roche #1119915] 
Sodium acetate [Univar #679-500G] 
 
Protocol: 
 
1.  Prepare bacterial cultures containing the required plasmid by inoculating a loopful of glycerol stock plasmid into 1L Terrific 
Broth (containing appropriate antibiotic). Incubate O/N at 37
oC with shaking. 
2.  Centrifuge at 2,500g, 4
oC, 10min. 
3.  Resuspend pellet in 50mL TEG swelling buffer at 4
oC. Add 100mL Lysis buffer and incubate on ice for 10min. 
4.  Add 75mL High Salt Neutralisation buffer (a white precipitate will form). Centrifuge at 2,500g, 4
oC, 10min. 
5.  Pour the supernatant through sterile gauze and add an equal volume of isopropanol. Centrifuge at 2,500g, 4
oC, 10min. 
6.  Pour off the supernatant and resuspend the pellet in 20mL double-deionised H2O (dd H2O). Transfer the solution to a 
polypropylene tube. 
7.  Add 20mL LiCl solution at 4
oC, mix and stand on ice for 10min. Centrifuge at 2,500g, 4
oC, 15min. Transfer the supernatant to 
a fresh polypropylene tube and discard pellet. 
8.  Extract the supernatant with an equal volume of phenol/ chloroform/ isoamyl alcohol.  Centrifuge at 1,800g, 20
oC, 5min. 
9.  Transfer the aqueous phase to a polypropylene tube and add 40mL isopropanol. Mix by inversion. Centrifuge at 2,500g, 4
oC, 
10min. Discard the supernatant. 
10.  Briefly dry the pellet and dissolve in 0.4mL ddH2O. Transfer to an eppendorf. 
11. Add  4µL RNase and incubate at 37
oC for 15min. 
12. Add  40µL 3M sodium acetate (pH 4.8) and 1mL ethanol.  Leave on dry ice for 15min (or at -20
oC overnight). Centrifuge at 
13,000g, 30min at 20
oC. 
13.  Wash pellet 1mL 70% ethanol and centrifuge at 13,000g, 5min at 20
oC.  
14.  Briefly dry pellet and resuspend in ddH2O. 
15.  Read OD @ 260nm and 280nm. 
 
Protocol 2: Intramuscular immunisation of DNA constructs 
 
Reagents: 
 
Insulin syringes, Ultra fine needle 29 Gauge (0.33mm x 12.7mm) [Becton Dickinson #326769] 
Marcain, 0.5% Bupivacaine [Astra #6641000] 
Pyrogen-free saline, 0.9% sodium chloride [Astra Zeneca #217904] 
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Protocol: 
 
1.  Mice (4 week old male BALB/c) are restrained by grasping the skin behind the ears with the thumb and index finger and 
tucking the tail underneath the little finger (as per i.p. injections). The legs are then sprayed with 70% ethanol to enable clear 
identification of the tibialis anterior (TA) muscle for intramuscular inoculation. 
2. 20µL 0.5% bupivacaine inoculated bilaterally via TA muscle. 
3.  5 days later, DNA constructs (200µg/mouse) are inoculated by the intramuscular route. Dilute DNA in 50µL volume of sterile 
pyrogen-free saline (4µg/µL).  
4.  Inoculate mice with 25µL DNA preparation bilaterally via the TA muscle.  
5.  Allow 14 days for intramuscular protein expression from the DNA constructs prior to viral challenge. 
 